[go: up one dir, main page]

TNSN03155A1 - Vaccination unidose avec mycoplasma hyopneumoniae - Google Patents

Vaccination unidose avec mycoplasma hyopneumoniae

Info

Publication number
TNSN03155A1
TNSN03155A1 TNPCT/IB2002/002121A TNSN03155A TNSN03155A1 TN SN03155 A1 TNSN03155 A1 TN SN03155A1 TN SN03155 A TNSN03155 A TN SN03155A TN SN03155 A1 TNSN03155 A1 TN SN03155A1
Authority
TN
Tunisia
Prior art keywords
vaccine
hyo
single dose
mycoplasma hyopneumoniae
dose vaccination
Prior art date
Application number
TNPCT/IB2002/002121A
Other languages
English (en)
Inventor
Robin Lee Keich
Lisa Grace Sabbadini
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23168589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN03155(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN03155A1 publication Critical patent/TNSN03155A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/87—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE DES METHODES POUR LE TRAITEMENT OU LA PREVENTION D'UNE MALADIE OU AFFECTION CHEZ UN ANIMAL, PROVOQUEE PAR UNE INFECTION PAR MYCOPLASMA HYOPNEUMONIAE (M.HYO) EN ADMINISTRANT A L'ANIMAL AGE D'APPROXIMATIVEMENT TROIS (3) A DIX (10) JOURS UNE DOSE UNIQUE D'UNE QUANTITE EFFICACE D'UN VACCIN A M.HYO. LE VACCIN A M. HYO PEUT ETRE UNE PREPARATION VIVANTE, INACTIVEE OU MODIFIEE, DE CELLULES ENTIERES OU PARTIELLES, UN VACCIN A SOUS-UNITE, OU UN VACCIN A ACIDE NUCLEIQUE OU VACCIN A ADN. LE VACCIN A M. HYO ADMINISTRE CONFORMEMENT A LA PRESENTE INVENTION PEUT ETRE SYNTHETISE OU PRODUIT PAR RECOMBINAISON.
TNPCT/IB2002/002121A 2001-07-02 2002-06-07 Vaccination unidose avec mycoplasma hyopneumoniae TNSN03155A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30263601P 2001-07-02 2001-07-02

Publications (1)

Publication Number Publication Date
TNSN03155A1 true TNSN03155A1 (fr) 2005-12-23

Family

ID=23168589

Family Applications (1)

Application Number Title Priority Date Filing Date
TNPCT/IB2002/002121A TNSN03155A1 (fr) 2001-07-02 2002-06-07 Vaccination unidose avec mycoplasma hyopneumoniae

Country Status (42)

Country Link
US (3) US6846477B2 (fr)
EP (3) EP1474067B2 (fr)
JP (1) JP2005515162A (fr)
KR (1) KR20040030785A (fr)
CN (3) CN1551781B (fr)
AP (1) AP2003002937A0 (fr)
AR (1) AR034678A1 (fr)
AT (1) ATE412426T2 (fr)
AU (1) AU2002309109B2 (fr)
BG (1) BG66481B1 (fr)
BR (1) BR0210804A (fr)
CA (1) CA2451626C (fr)
CY (1) CY1108749T1 (fr)
CZ (1) CZ305781B6 (fr)
DE (1) DE60229666D1 (fr)
DK (3) DK1474067T4 (fr)
DO (1) DOP2002000431A (fr)
EA (1) EA009901B1 (fr)
ES (3) ES2550458T3 (fr)
GT (1) GT200200138A (fr)
HK (1) HK1207584A1 (fr)
HR (1) HRP20031079A2 (fr)
HU (1) HU230246B1 (fr)
IL (1) IL159349A0 (fr)
IS (1) IS7076A (fr)
MA (1) MA27047A1 (fr)
MX (1) MXPA03011599A (fr)
NO (1) NO342654B1 (fr)
NZ (1) NZ530106A (fr)
OA (1) OA12638A (fr)
PA (1) PA8549701A1 (fr)
PE (1) PE20030285A1 (fr)
PL (1) PL209773B1 (fr)
PT (3) PT1474067E (fr)
SK (1) SK288010B6 (fr)
TN (1) TNSN03155A1 (fr)
TW (1) TWI329514B (fr)
UA (1) UA78707C2 (fr)
UY (1) UY27366A1 (fr)
WO (1) WO2003003941A2 (fr)
YU (1) YU102203A (fr)
ZA (1) ZA200309698B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
WO2006056841A1 (fr) * 2004-11-24 2006-06-01 Pharmacia & Upjohn Company Llc Vaccins multisouches a base de mycoplasma hyopneumoniae
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
DK1968630T5 (en) * 2005-12-29 2018-08-13 Boehringer Ingelheim Vetmedica Inc MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS.
SG170792A1 (en) 2005-12-29 2011-05-30 Boehringer Ingelheim Vetmed Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
WO2007103042A2 (fr) * 2006-03-03 2007-09-13 Merial Limited Vaccin contre le mycoplasma hyopneumoniae
EP2099927A4 (fr) * 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Procedes de reduction des flambees des maladies associees au circovirus porcin
EP2101815A4 (fr) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Procede efficace de traitement du circovirus porcin et des infections par lawsonia intracellularis
WO2008076915A2 (fr) 2006-12-15 2008-06-26 Boehringer Ingelheim Vetmedica, Inc. Traitement des porcs avec l'antigène du pcv2
EP1941903A1 (fr) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxie et traitement du PRDC
EP1958644A1 (fr) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prévention et traitement du PCVD subclinique
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009061798A1 (fr) * 2007-11-06 2009-05-14 Wyeth Vaccin à virus vivant avirulent avec adjuvant contre mycoplasma hyopneumoniae
CA2710558A1 (fr) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. Particule de type virus pcv2 orf2 avec insertion d'acides amines etrangers
CN101236206B (zh) * 2008-01-17 2014-10-15 中国兽医药品监察所 一种猪肺炎支原体重组抗原elisa检测试剂盒
CN101980720A (zh) * 2008-01-23 2011-02-23 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2猪肺炎支原体致免疫组合物及其制备方法
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
ES2728949T3 (es) 2008-06-27 2019-10-29 Zoetis Services Llc Composiciones adyuvantes novedosas
TWI583403B (zh) 2009-06-04 2017-05-21 國立感染症研究所 黴漿菌感染症用疫苗
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
EP2550362B1 (fr) 2010-03-25 2017-01-04 Oregon Health&Science University Glycoprotéines du cmv et vecteurs recombinés
ES2559445T3 (es) 2010-05-11 2016-02-12 Intervet International B.V. Vacuna contra Mycoplasma hyopneumoniae apta para la administración en presencia de anticuerpos de origen materno
KR102157718B1 (ko) * 2010-07-26 2020-09-18 큐 바이올로직스 인코포레이티드 면역원성 소염 조성물
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
EP2609428B1 (fr) * 2010-08-27 2016-02-10 Intervet International B.V. Test d'activité biologique destiné à des formulations de vaccin
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
CA2866199A1 (fr) * 2012-03-07 2013-09-12 Ceva Sante Animale Nouveau vaccin veterinaire
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9878027B2 (en) * 2012-12-28 2018-01-30 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
EP2938747B1 (fr) 2012-12-28 2019-05-01 Boehringer Ingelheim Vetmedica GmbH Procédé de fabrication d'un vaccin de mycoplasme
WO2014121433A1 (fr) * 2013-02-05 2014-08-14 财团法人农业科技研究院 Vaccin sous-unitaire anti-mycoplasma spp.
CN104338125A (zh) * 2013-07-29 2015-02-11 普莱柯生物工程股份有限公司 一种猪肺炎支原体抗原在预防和治疗猪呼吸道疾病综合征方面的应用
US10117921B2 (en) 2013-09-19 2018-11-06 Zoetis Services Llc Oil-based adjuvants
CN105658660A (zh) 2013-10-02 2016-06-08 勃林格殷格翰动物保健公司 Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
UA116697C2 (uk) * 2013-11-21 2018-04-25 Агрікалчерал Текнолоджи Рісьоч Інстітьют Композиція для запобігання зараженню видами роду mycoplasma
CN105012948B (zh) * 2014-04-18 2019-07-30 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
CN104248753B (zh) * 2014-05-15 2017-07-28 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
AU2016206525A1 (en) 2015-01-16 2017-07-13 United States Of America, As Represented By The Secretary Of Agriculture Foot-and-mouth disease vaccine
KR20160099223A (ko) * 2015-02-12 2016-08-22 강원대학교산학협력단 마이코플라스마 하이오뉴모니애 박테린 백신 및 이의 제조방법
WO2018030878A1 (fr) * 2016-08-12 2018-02-15 주식회사 이노백 COMPOSITION VACCINALE DESTINÉE À PRÉVENIR L'INFECTION PAR LES MYCOPLASMES PORCINS COMPRENANT UNE PROTÉINE RECOMBINÉE<i />
RU2668799C1 (ru) * 2017-09-08 2018-10-02 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
CN108101969A (zh) * 2017-11-13 2018-06-01 南京大爻网络科技有限公司 一种与猪支原体肺炎相关的抗原及其应用
RU2695679C1 (ru) * 2018-09-11 2019-07-25 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp.
RU2759427C2 (ru) * 2019-07-08 2021-11-12 Эгрикалчурал Текнолоджи Рисерч Инститьют Субъединичная вакцина против mycoplasma spp
CN117305192A (zh) * 2023-12-01 2023-12-29 北京瑞阳瑞泰生物科技有限公司 一种猪肺炎支原体rt02株、疫苗组合物及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252328A (en) 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (fr) * 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Antigène de mycoplasma hyopneumoniae et ses utilisations
EP0307976B1 (fr) 1987-09-18 1993-06-23 Akzo Nobel N.V. Vaccin contre mycoplasma
AU7682091A (en) 1990-04-02 1991-10-30 Synergen, Inc. Polypeptides useful in diagnosis of and treatment against mycoplasma infections in animals
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
ES2112274T5 (es) 1990-05-29 2006-03-01 Wyeth Holdings Corporation Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma.
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP0475185A1 (fr) 1990-08-27 1992-03-18 Nippon Flour Mills Co., Ltd. ADN's encodant les antiqèues superficiels de mycoplasma hyopneumonique, fragments d'ADN pour les amorces, peptides recombinants antigéniques et méthode diagnostique de pneumonie mycoplasmale de porc les utilisant
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
ES2225825T3 (es) 1992-09-28 2005-03-16 Wyeth Holdings Corporation Procedimiento de mejora de las respuestas inmunitarias mediadas por celulas.
US5530874A (en) 1993-02-02 1996-06-25 3Com Corporation Network adapter with an indication signal mask and an interrupt signal mask
WO1995009870A1 (fr) 1993-10-07 1995-04-13 Iowa State University Research Foundation, Inc. CARACTERISATION D'ADHESINES DE $i(MYCOPLASMA HYOPNEUMONIAE)
NZ285324A (en) 1994-05-10 1998-08-26 American Home Prod Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US6440408B2 (en) 1996-09-30 2002-08-27 University Of Arkansas Method of treatment
EP0846468B1 (fr) 1996-12-05 2004-06-09 Akzo Nobel N.V. Mycoplasma synoviae non virulent et vaccin de celui-ci
JP2001523481A (ja) 1997-11-26 2001-11-27 アイオワ ステイト ユニヴァーシティ リサーチ ファウンデーション インコーポレイテッド 組換えｈｙｏ肺炎マイコプラズマワクチン
AU6128900A (en) * 1999-09-29 2001-04-05 Pfizer Products Inc. Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs

Also Published As

Publication number Publication date
AP2003002937A0 (en) 2003-12-31
SK288010B6 (sk) 2012-10-02
EA200301323A1 (ru) 2005-06-30
PT2842569T (pt) 2019-06-17
OA12638A (en) 2006-06-15
MA27047A1 (fr) 2004-12-20
DK1474067T4 (en) 2017-10-16
US20030109473A1 (en) 2003-06-12
PE20030285A1 (es) 2003-03-27
ES2312580T3 (es) 2009-03-01
CA2451626C (fr) 2011-05-31
EP1474067A2 (fr) 2004-11-10
DK2027873T3 (en) 2015-11-09
YU102203A (sh) 2006-05-25
ATE412426T2 (de) 2008-11-15
CZ305781B6 (cs) 2016-03-16
EP2027873B8 (fr) 2015-11-11
MXPA03011599A (es) 2005-03-07
BG66481B1 (bg) 2015-02-27
PL209773B1 (pl) 2011-10-31
PT1474067E (pt) 2008-11-14
PL373367A1 (en) 2005-08-22
EP2027873B1 (fr) 2015-09-09
DOP2002000431A (es) 2003-01-15
IL159349A0 (en) 2004-06-01
PA8549701A1 (es) 2003-01-24
CY1108749T1 (el) 2014-04-09
EP1474067B2 (fr) 2017-08-16
EP1474067B1 (fr) 2008-10-29
CN1551781A (zh) 2004-12-01
US20050013823A1 (en) 2005-01-20
ES2550458T3 (es) 2015-11-10
BR0210804A (pt) 2005-05-03
ES2312580T5 (es) 2017-12-11
KR20040030785A (ko) 2004-04-09
EP2027873A1 (fr) 2009-02-25
EP2842569B1 (fr) 2019-04-10
NZ530106A (en) 2007-06-29
CN1551781B (zh) 2013-01-02
UA78707C2 (en) 2007-04-25
HK1068250A1 (en) 2005-04-29
HUP0400434A2 (en) 2007-08-28
EP2842569A1 (fr) 2015-03-04
DE60229666D1 (de) 2008-12-11
WO2003003941A2 (fr) 2003-01-16
NO20035762L (no) 2004-02-02
EA009901B1 (ru) 2008-04-28
US6846477B2 (en) 2005-01-25
CN102872456A (zh) 2013-01-16
CN101524532B (zh) 2014-03-19
AR034678A1 (es) 2004-03-03
HK1207584A1 (en) 2016-02-05
ZA200309698B (en) 2014-04-30
GT200200138A (es) 2003-05-15
UY27366A1 (es) 2003-04-30
PT2027873E (pt) 2015-11-03
CA2451626A1 (fr) 2003-01-16
ES2729579T3 (es) 2019-11-04
HK1180224A1 (zh) 2013-10-18
SK15792003A3 (sk) 2005-09-08
HK1134900A1 (zh) 2010-05-20
USRE44399E1 (en) 2013-07-30
DK2842569T3 (da) 2019-05-20
AU2002309109B2 (en) 2007-12-13
NO342654B1 (no) 2018-06-25
CN101524532A (zh) 2009-09-09
JP2005515162A (ja) 2005-05-26
HU230246B1 (hu) 2015-11-30
WO2003003941A3 (fr) 2004-07-29
BG108546A (bg) 2005-02-28
TWI329514B (en) 2010-09-01
CZ20033466A3 (cs) 2005-06-15
CN102872456B (zh) 2016-01-20
DK1474067T3 (da) 2008-12-08
IS7076A (is) 2003-12-15
HRP20031079A2 (en) 2005-10-31
EP1474067A4 (fr) 2005-08-10

Similar Documents

Publication Publication Date Title
TNSN03155A1 (fr) Vaccination unidose avec mycoplasma hyopneumoniae
TNSN03154A1 (fr) Vaccin a mycoplasma bovis et methodes pour reduire la pneumonie chez des animaux.
YU99102A (sh) Postupci i kompozicija za oralnu vakcinaciju
MA27388A1 (fr) Vaccin pour des infections du systeme respiratoire et du systeme reproducteur chez les bovins
BR0211049A (pt) Método de tratamento ou prevenção de doenças ou disfunções e uso de mycoplasma hyopneumoniae
JP2005534752A5 (fr)
KR20010108388A (ko) 수태율 증진 조성물
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ITMI941048A1 (it) Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
KR20090053967A (ko) 웨스트 나일 백신
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
JP2024174906A (ja) 運動系の疾患の治療のために有用な組成物
US20100291115A1 (en) Pharmaceutical composition for the sublingual administration of vaccines, method for the preparation of the same and uses thereof
RU2093177C1 (ru) Препарат &#34;дина&#34; для лечения и профилактики заболеваний млекопитающих, птиц и рептилий
RU2232501C2 (ru) Способ повышения естественной резистентности животных
FR2507479A1 (fr) Vaccin contre les infections chlamydiennes des animaux d&#39;elevage
JP2004210769A (ja) 魚類冷水病ワクチン
RU2165757C1 (ru) Лечебно-профилактическое средство для молодняка сельскохозяйственных животных и птицы
RU2146532C1 (ru) Способ лечения и профилактики трихофитии и микроспории пушных зверей и мелких плотоядных животных
RU2004118613A (ru) Способ профилактики и лечения дирофиляриоза собак
RU2195938C1 (ru) Способ получения регидратационного средства &#34;регидратон свф&#34;
Lawson et al. ERA strain rabies vaccine: oral vaccination of nonhuman primates
Getachew et al. Treatment of epizootic lymphangitis in cart horses through participatory method.
WO2004103408A2 (fr) Composition vaccinale comprenant du phosphate de fer a titre d’adjuvant vaccinal
UA65816A (en) Vaccine velshisan for preventing toxicoinfections caused by clostridium perfringens